391 related articles for article (PubMed ID: 23447565)
1. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
Haq R; Yokoyama S; Hawryluk EB; Jönsson GB; Frederick DT; McHenry K; Porter D; Tran TN; Love KT; Langer R; Anderson DG; Garraway LA; Duncan LM; Morton DL; Hoon DS; Wargo JA; Song JS; Fisher DE
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4321-6. PubMed ID: 23447565
[TBL] [Abstract][Full Text] [Related]
2. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
3. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
4. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.
Haq R; Shoag J; Andreu-Perez P; Yokoyama S; Edelman H; Rowe GC; Frederick DT; Hurley AD; Nellore A; Kung AL; Wargo JA; Song JS; Fisher DE; Arany Z; Widlund HR
Cancer Cell; 2013 Mar; 23(3):302-15. PubMed ID: 23477830
[TBL] [Abstract][Full Text] [Related]
6. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
Sabbah M; Krayem M; Najem A; Sales F; Miller W; Del Rincon S; Awada A; Ghanem GE; Journe F
Mol Cancer Res; 2021 Jul; 19(7):1221-1233. PubMed ID: 33741716
[TBL] [Abstract][Full Text] [Related]
8. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
9. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Mazzio EA; Soliman KFA
Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
[TBL] [Abstract][Full Text] [Related]
10. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.
Smith MP; Sanchez-Laorden B; O'Brien K; Brunton H; Ferguson J; Young H; Dhomen N; Flaherty KT; Frederick DT; Cooper ZA; Wargo JA; Marais R; Wellbrock C
Cancer Discov; 2014 Oct; 4(10):1214-1229. PubMed ID: 25256614
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.
Gopal YN; Rizos H; Chen G; Deng W; Frederick DT; Cooper ZA; Scolyer RA; Pupo G; Komurov K; Sehgal V; Zhang J; Patel L; Pereira CG; Broom BM; Mills GB; Ram P; Smith PD; Wargo JA; Long GV; Davies MA
Cancer Res; 2014 Dec; 74(23):7037-47. PubMed ID: 25297634
[TBL] [Abstract][Full Text] [Related]
12. Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF.
Liu X; Li Z; Li M; Chai J; He S; Wu J; Xu J
Oncol Rep; 2020 Jul; 44(1):360-370. PubMed ID: 32319656
[TBL] [Abstract][Full Text] [Related]
13. A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.
Choi J; Xu M; Makowski MM; Zhang T; Law MH; Kovacs MA; Granzhan A; Kim WJ; Parikh H; Gartside M; Trent JM; Teulade-Fichou MP; Iles MM; Newton-Bishop JA; Bishop DT; MacGregor S; Hayward NK; Vermeulen M; Brown KM
Nat Genet; 2017 Sep; 49(9):1326-1335. PubMed ID: 28759004
[TBL] [Abstract][Full Text] [Related]
14. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
Kim JH; Ahn JH; Lee M
Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
18. MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
Aida S; Sonobe Y; Tanimura H; Oikawa N; Yuhki M; Sakamoto H; Mizuno T
Cancer Lett; 2017 Nov; 409():116-124. PubMed ID: 28923400
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
[TBL] [Abstract][Full Text] [Related]
20. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
